Devyser Diagnostics AB (publ) (STO:DVYSR)
92.50
-0.70 (-0.75%)
Apr 29, 2026, 1:25 PM CET
Devyser Diagnostics AB Company Description
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results.
The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
Devyser Diagnostics AB (publ)
| Country | Sweden |
| Founded | 2004 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Jan Wahlstrom |
Contact Details
Address: Bränningevägen 12 Årsta, 120 54 Sweden | |
| Phone | 46 8 56 21 58 50 |
| Website | devyser.com |
Stock Details
| Ticker Symbol | DVYSR |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0016588867 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Jan Wahlstrom | Chief Executive Officer |
| Sabina Berlin | Chief Financial Officer |
| Michael Uhlin Ph.D. | Chief Scientific Officer |
| Camilla Wiberg | Chief Human Resource Officer |
| John Murad | Vice President and GM of Devyser US |